Treatment Strategies for Unruptured Intracranial Aneurysms in the Chinese Population China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA)

Sponsor
Beijing Tiantan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05844163
Collaborator
Huashan Hospital (Other), The First Affiliated Hospital of Zhengzhou University (Other), First Affiliated Hospital of Fujian Medical University (Other), Shanxi Provincial People's Hospital (Other)
21,041
1
35
600.8

Study Details

Study Description

Brief Summary

The goal of this prospective observational cohort study is to learn about treatment strategies for unruptured intracranial aneurysms in the Chinese population. The main questions it aims to answer are:

  • To establish a cohort of patients with intracranial unruptured aneurysm and explore the optimal clinical treatment strategy.

  • To establish clinical management path for patients with unruptured intracranial aneurysm.

According to the treatment of all patients with unruptured intracranial aneurysm, they were divided into the following groups: 1. Conservative treatment group; 2. Intracranial aneurysm clipping group; 3. Coil embolization or stent-assisted coil embolization group; 4. Flow diversion group.

Condition or Disease Intervention/Treatment Phase
  • Other: observation

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
21041 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Treatment Strategies for Unruptured Intracranial Aneurysms in the Chinese Population China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA)
Actual Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Conservative treatment group

Patients in conservative treatment group receive optimal drug therapy including appropriate blood pressure control and other measures.

Other: observation
observation

Intracranial aneurysm clipping group

Patients in Intracranial aneurysm clipping group receive neurosurgical clipping.

Other: observation
observation

Coil embolization or stent-assisted coil embolization group

Patients in coil embolization or stent-assisted coil embolization group receive coil embolization or stent-assisted coil embolization according to individualized condition.

Other: observation
observation

Flow diversion group.

Patients in flow diversion group receive flow diverters.

Other: observation
observation

Outcome Measures

Primary Outcome Measures

  1. Primary Outcome [2 years]

    Functional outcomes(modified Rankin Scale,mRS) at 2 years after treatment decision

Secondary Outcome Measures

  1. MACCE events [1 years]

    Incidence of major adverse cardiovascular/cerebrovascular events (MACCE events) in patients with atherosclerotic heart disease within 1 year after treatment decision.

  2. cardiovascular/cerebrovascular events [2 years]

    Incidence of cardiovascular/cerebrovascular events in 2 years after receiving different treatment strategies.

  3. Cost [2 years]

    Costs associated with unruptured intracranial aneurysms within 2 years after treatment with different strategies.

  4. Aneurysm-related bleeding events [2 years]

    Incidence of aneurysmal-related bleeding events within 2 years after receiving different treatment strategies.

  5. Mortality associated with intracranial aneurysms [2 years]

    Mortality associated with intracranial aneurysms within 2 years after treatment with different strategies

  6. All-cause mortality [2 years]

    All-cause mortality of patients within 2 years after different treatment strategies.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. age > 18 years. B. at least one intracranial aneurysm needs to be treated by craniotomy, endovascular treatment or combined surgery.
Exclusion Criteria:
  1. Ruptured intracranial aneurysms, accompanied by subarachnoid hemorrhage or cerebral hemorrhage ;

  2. Traumatic, infectious and atrial myxoma-associated intracranial aneurysms ;

  3. Combined with cerebrovascular malformations ;

  4. Combined with brain tumors or malignant tumors in other parts ;

  5. with acute myocardial infarction ;

  6. in acute or chronic heart failure ( New York Heart Association classification > 2 points ) ;

  7. combined with systemic connective tissue disease and systemic rheumatic disease ;

  8. Due to other diseases, or poor general condition, the expected survival time is not more than 12 months ;

  9. during pregnancy and perinatal period

Contacts and Locations

Locations

Site City State Country Postal Code
1 Capital Medical University Affiliated Beijing Tiantan Hospital Beijing Beijing China

Sponsors and Collaborators

  • Beijing Tiantan Hospital
  • Huashan Hospital
  • The First Affiliated Hospital of Zhengzhou University
  • First Affiliated Hospital of Fujian Medical University
  • Shanxi Provincial People's Hospital

Investigators

  • Study Chair: Wang shuo, M.D., Beijing Tiantan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wang Shuo, Director of Department of Cerebrovascular Neurosurgery, Beijing Tiantan Hospital
ClinicalTrials.gov Identifier:
NCT05844163
Other Study ID Numbers:
  • KY2022-226
First Posted:
May 6, 2023
Last Update Posted:
May 6, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2023